Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial

Lin-Huang Huang, Chia-Yu Liu, Li-Yu Wang, Chien-Jung Huang, Chung-Hua Hsu, Lin-Huang Huang, Chia-Yu Liu, Li-Yu Wang, Chien-Jung Huang, Chung-Hua Hsu

Abstract

Background: This study aims to examine the effects of green tea extract (GTE) supplement on overweight and obese women with high levels of low density lipoprotein-cholesterol (LDL-C).

Methods: The randomized, double-blind, crossover and placebo-controlled clinical trial was conducted from August 2012 to December 2013. Seventy-three out of 90 subjects aged between 18 and 65 years, with body mass index (BMI) ≥ 27 kg/m2 and LDL-C ≥ 130 mg/dl were included in the analysis. The subjects were randomly divided into Groups A and B. Group A received GTE supplement treatment for the first 6 weeks, while Group B received placebo daily. After 6 weeks of treatment and 14 days of washout period, Group A switched to placebo and Group B switched to GTE treatment for 6 weeks. The reduction of LDL-C level between treatments was assessed as the outcome. Additionally, anthropometric measurements, plasma lipoproteins and hormone peptides of both groups were measure at the beginning of weeks 6, 8, and 14 after treatment.

Results: Subjects treated with GTE (n = 73) for 6 weeks showed significant differences, with 4.8% (p = 0.048) reduction in LDL-C and 25.7% (p = 0.046) increase in leptin. However, there was no statistical difference in the levels of total cholesterol, triglyceride and high density lipoprotein between the GTE and placebo groups after treatments.

Conclusions: This study shows that green tea extract effectively increases leptin and reduces LDL in overweight and obese women after 6 weeks of treatment even though there were no significant changes in other biochemical markers related to overweight.

Trial registration: This clinical trial is registered with ClinicalTrials.gov: NCT02116517 on 17 April 2014. Retrospectively registered. The first patient enrolled in October 2012 and the study was completed December 2013.

Keywords: EGCG; Epigallocatechin gallant; Green tea extract; Hyperlipidemia; LDL-C; Leptin; Low density lipoprotein; Obesity.

Conflict of interest statement

Ethics approval and consent to participate

The protocol for this clinical research received ethical approval by the Taipei City Hospital Institutional Review Board on 26 July 2012. The trial was register with ClinicalTrials.gov on 17 April 2014: NCT02116517. All participants gave written informed consent by signing an consent form and had the freedom to withdraw from the study at any time. The study adheres to CONSORT guidelines.

Consent for publication

No details, images or videos of specific individuals are included in the report therefore no consent for publication needed. (N/A).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Trial Profile and Design

References

    1. Malik VS, Willett WC, Hu FB. Global obesity: Trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9(1):13–27. doi: 10.1038/nrendo.2012.199.
    1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating, G National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–567. doi: 10.1016/S0140-6736(10)62037-5.
    1. Huang LH, Liao YL, Hsu CH. Waist circumference is a better predictor than body mass index of insulin resistance in type 2 diabetes. Obes Res Clin Pract. 2012;6(4):314–320. doi: 10.1016/j.orcp.2011.11.003.
    1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease adn stroke statisticsc-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.
    1. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007;15:4674–4699. doi: 10.1016/j.bmc.2007.04.031.
    1. Apovian CM, Gokce N. Obesity and cardiovascular disease. Circulation. 2012;125(9):1178–1182. doi: 10.1161/CIRCULATIONAHA.111.022541.
    1. Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev CardiovascTher. 2012;10(7):933–939. doi: 10.1586/erc.12.74.
    1. Gu GL, Xu XL, Yang QY, Zeng RL. Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease. Med Sci Monit. 2014;20:2824–2829. doi: 10.12659/MSM.892711.
    1. Zamani B, Saatlo BB, Naghavi-Behzad M, Taqizadeh-Jahed M, Alikhah H, Abbasnezhad M. Effects of high versus low-dose atorvastatin on high sensitive C-reactive protein in acute coronary syndrome. Niger Med J. 2014;55(6):490–494. doi: 10.4103/0300-1652.144704.
    1. Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, Visseren FL, Bots ML, Spiering W. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2014;181C:193–199.
    1. Suh Y, Kim BK, Shin DH, Kim JS, Ko YG, Choi D, Jang Y, Hong MK. Impact of statin treatment on strut coverage after drug-eluting stent implantation. Yonsei Med J. 2015;56(1):45–52. doi: 10.3349/ymj.2015.56.1.45.
    1. Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4–11. doi: 10.1016/j.dld.2014.07.170.
    1. Kalantari S, Naghipour M. Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. Adv Biomed Res. 2014;3:168. doi: 10.4103/2277-9175.139133.
    1. Sun L, Lee DE, Tan WJ, Ranawana DV, Quek YC, Goh HJ, Henry CJ. Glycaemic index and glycaemic load of selected popular foods consumed in Southeast Asia. Br J Nutr. 2015;113(5):843–848. doi: 10.1017/S0007114514004425.
    1. Keske MA, Ng HL, Premilovac D, Rattigan S, Kim JA, Munir K, Yang P, Quon MJ. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr Med Chem. 2015;22(1):59–69. doi: 10.2174/0929867321666141012174553.
    1. Bajerska J, Mildner-Szkudlarz S, Walkowiak J. Effects of rye bread enriched with green tea extract on weight maintenance and the characteristics of metabolic syndrome following weight loss: a pilot study. J Med Food. 2015;18(6):698–705. doi: 10.1089/jmf.2014.0032.
    1. Yarmolinsky J, Gon G, Edwards P. Effect of tea on blood pressure for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2015;73(4):236–246. doi: 10.1093/nutrit/nuv001.
    1. Sikand G, Kris-Etherton P, Boulos NM. Impact of functional foods on prevention of cardiovascular disease and diabetes. Curr Cardiol Rep. 2015;17(6):39. doi: 10.1007/s11886-015-0593-9.
    1. Kim HM, Kim J. The effects of green tea on obesity and type 2 diabetes. Diabetes Metab J. 2013;37:173–175. doi: 10.4093/dmj.2013.37.3.173.
    1. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander J. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr. 1999;70:1040–1045. doi: 10.1093/ajcn/70.6.1040.
    1. Diepvens K, Westerterp KR, Westererp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Phys Regul Integr Comp Phys. 2007;292:R77–R85.
    1. Tian C, Ye X, Zhang R, Long J, Ren W, Ding S, Liao D, Jin X, Wu H, Xu S, Ying C. Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARgamma-adiponectin pathway. PLoS One. 2013;8:e53796. doi: 10.1371/journal.pone.0053796.
    1. Goto T, Saito Y, Morikawa K, Kanamaru Y, Nagaoka S. Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. Br J Nutr. 2012;107:769–773. doi: 10.1017/S0007114511003758.
    1. Li Y, Zhao S, Zhang W, Zhao P, He B, Wu N, Han P. Epigallocatechin-3-O-gallate (EGCG) attenuates FFAs-induced peripheral insulin resistance through AMPK pathway and insulin signaling pathway in vivo. Diabetes Res Clin Pract. 2011;93:205–214. doi: 10.1016/j.diabres.2011.03.036.
    1. Sone Toshimasa, Kuriyama Shinichi, Nakaya Naoki, Hozawa Atsushi, Shimazu Taichi, Nomura Kozue, Rikimaru Shouzo, Tsuji Ichiro. Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food & Nutrition Research. 2011;55(1):8326. doi: 10.3402/fnr.v55i0.8326.
    1. Hursel R, Viechtbauer W, Dulloo AG, Tremblay A, Tappy L, Rumpler W, Westerterp-Plantenga MS. The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis. Obes Rev. 2011;12:e573–e581. doi: 10.1111/j.1467-789X.2011.00862.x.
    1. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007;81:519–533. doi: 10.1016/j.lfs.2007.06.011.
    1. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, Epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr. 2008;138:1677–1683. doi: 10.1093/jn/138.9.1677.
    1. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res. 2006;50(2):176–187. doi: 10.1002/mnfr.200500102.
    1. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, Lyons TJ. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010;29(1):31–40. doi: 10.1080/07315724.2010.10719814.
    1. Fujiwara T, Yoshioka S, Yosioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045:studies in KK and ob/obmice and Zucker fatty rats. Diabetes. 1988;37:1549–1558. doi: 10.2337/diab.37.11.1549.
    1. Rocha A, Bolin AP, Cardoso CA, Otton R. Green tea extract activated AMPK and ameliorates white adipose tissue metabolic dysfunction induced by obesity. Eur J Nutr. 2015;55:2231–2244. doi: 10.1007/s00394-015-1033-8.
    1. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. J Clin Invest. 1983;73:1150–1162. doi: 10.1172/JCI111040.
    1. Hsu C, Hwang K, Chao C, Lin J, Kao S, Chou P. Effects of electroacupunture in reducing weight and waist circumference in obese women: a randomized crossover trial. Int J Obes. 2005;29(11):1379–1384. doi: 10.1038/sj.ijo.0802997.
    1. Hsu C, Tsai T, Kao Y, Hwang K, Tseng T, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008;27:363–370. doi: 10.1016/j.clnu.2008.03.007.
    1. Liu Chia-Yu, Huang Chien-Jung, Huang Lin-Huang, Chen I-Ju, Chiu Jung-Peng, Hsu Chung-Hua. Effects of Green Tea Extract on Insulin Resistance and Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes and Lipid Abnormalities: A Randomized, Double-Blinded, and Placebo-Controlled Trial. PLoS ONE. 2014;9(3):e91163. doi: 10.1371/journal.pone.0091163.
    1. Most J, van Can J, van Dijk J, Goossens G, Jocken J, Hospers J, Bendik I, Blaak E. A 3-day EGCG-supplementation reduces interstitial lactate concentration in skeletal muscle of overweight subjects. Sci Rep. 2015;5:17896. doi: 10.1038/srep178996.
    1. Noguiera de Amorim LM, Vaz SR, Ceserio G, Coelho A, Botelho P. Effect of green tea extract on bone mass and body composition in individuals with diabetes. J Funct Foods. 2018;40:589–594. doi: 10.1016/j.jff.2017.11.039.
    1. Yadav N, Arjuman A, Chandra N. Role of leptin on expression of low density lipoprotein receptor. Indian J Med Res. 2014;140(4):524–530.
    1. Lee Y, Yu X, Gonzales F, et al. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A. 2002;99(18):11848–11853. doi: 10.1073/pnas.182420899.
    1. Klok M. D., Jakobsdottir S., Drent M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity Reviews. 2007;8(1):21–34. doi: 10.1111/j.1467-789X.2006.00270.x.
    1. Genetics Home Referance [Internet]. LDLR ene. NHI; [updated 2018 Feb; cited 2018 Feb 27]. Available from: #.
    1. Yang CS, Zhang J, Zhang L, Huang J, Wang Y. Mechanisms of body weight reduction and metabolic syndrome alleviation by tea. Mol Nutr Food Res. 2016;60(1):160–174. doi: 10.1002/mnfr.201500428.
    1. Park H-K, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metab Clin Exp. 2015;64(1):24–34. doi: 10.1016/j.metabol.2014.08.004.
    1. Samavat H, Newman A, Wang R, Yuan J, Wu A, Kurzer M. Effect of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial. Am J Clin Nutr. 2016;104:1671–1682. doi: 10.3945/ajcn.116.137075.
    1. Tian C, Huang Q, Yang L, Legare S, Angileri F, Yang H, et al. Green tea consumption is associated with reduced incident CHD and improved CHD-related biomarkers in the Dongfeng-Tongji cohort. Sci Rep. 2016;6:24353. doi: 10.1038/srep24353.
    1. Yi L, Wang C, Huai Q, Guo F, Liu L, Feng R, Sun C. Effects of tea or tea extract on metabolic profiles in patients with type 2 diabetes mellitus: a meta-analysis of ten randomized controlled trials. Diabetes Metab Res Rev. 2016;32:2–10.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa